PMID- 7812004
OWN - NLM
STAT- MEDLINE
DCOM- 19950203
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 85
IP  - 2
DP  - 1995 Jan 15
TI  - Detection of residual leukemic cells in patients with acute promyelocytic 
      leukemia by the fluorescence in situ hybridization method: potential for 
      predicting relapse.
PG  - 495-9
AB  - The translocation between chromosomes 15 and 17, t(15;17)(q22-24;q11-21), is 
      present in the bone marrow cells of most patients with acute promyelocytic 
      leukemia (APL). Although conventional cytogenetic methods are useful for 
      diagnosing this disease, difficulties are experienced in detecting residual 
      disease among those patients who have achieved remission. In this study, we used 
      the fluorescence in situ hybridization (FISH) method to attempt to detect 
      residual leukemic cells in 10 APL patients in clinical remission. The duration of 
      remission ranged from 2 to 93 months at the time of study. Multiple bone marrow 
      samples were analyzed by FISH in most patients. In 6 patients, no cell with 
      t(15;17) was found. These patients remain in complete remission at present 
      (approximately 25 to 33 months since first studied by FISH). In 4 patients, low 
      frequencies of cells with t(15;17) were observed in at least one bone marrow 
      sample examined. All of these patients relapsed within 1 to 14 months. No cell 
      with t(15;17) was identified by the conventional G-banding method in any sample. 
      The FISH results correlated well with that of a two-round nested reverse 
      transcription polymerase chain reaction assay that was performed on the same 
      samples. Thus, our study suggests that FISH is potentially a useful tool for 
      detecting residual APL cells and for identifying patients at high risk of 
      relapse.
FAU - Zhao, L
AU  - Zhao L
AD  - Department of Laboratory Medicine, University of Texas M.D. Anderson Cancer 
      Center, Houston 77030.
FAU - Chang, K S
AU  - Chang KS
FAU - Estey, E H
AU  - Estey EH
FAU - Hayes, K
AU  - Hayes K
FAU - Deisseroth, A B
AU  - Deisseroth AB
FAU - Liang, J C
AU  - Liang JC
LA  - eng
GR  - CA 43585/CA/NCI NIH HHS/United States
GR  - CA 55164/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Oncogene Proteins, Fusion)
SB  - IM
GS  - PML
GS  - RAR&agr;
MH  - Base Sequence
MH  - Bone Marrow/*pathology
MH  - Bone Marrow Examination/*methods
MH  - Chromosome Banding
MH  - Chromosomes, Human, Pair 15/*ultrastructure
MH  - Chromosomes, Human, Pair 17/*ultrastructure
MH  - Double-Blind Method
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Leukemia, Promyelocytic, Acute/genetics/*pathology
MH  - Molecular Sequence Data
MH  - Neoplasm, Residual
MH  - Oncogene Proteins, Fusion/analysis
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Prospective Studies
MH  - Remission Induction
MH  - *Translocation, Genetic
EDAT- 1995/01/15 00:00
MHDA- 1995/01/15 00:01
CRDT- 1995/01/15 00:00
PHST- 1995/01/15 00:00 [pubmed]
PHST- 1995/01/15 00:01 [medline]
PHST- 1995/01/15 00:00 [entrez]
AID - S0006-4971(20)71276-0 [pii]
PST - ppublish
SO  - Blood. 1995 Jan 15;85(2):495-9.